Objective-Angiogenesis is regulated by the balance between pro-and antiangiogenic factors and by extracellular matrix protein interactions. Fibroblast growth factor 2 (FGF2) is a major proangiogenic inducer inhibited by the interaction with the soluble pattern recognition receptor long pentraxin 3 (PTX3). PTX3 is locally coexpressed with its ligand tumor necrosis factor-stimulated gene-6 (TSG-6), a secreted glycoprotein that cooperates with PTX3 in extracellular matrix assembly. Here, we characterized the effect of TSG-6 on PTX3/FGF2 interaction and FGF2-mediated angiogenesis. Methods and Results-Solid phase binding and surface plasmon resonance assays show that TSG-6 and FGF2 bind the PTX3 N-terminal domain with similar affinity. Accordingly, TSG-6 prevents FGF2/PTX3 interaction and suppresses the inhibition exerted by PTX3 on heparan sulfate proteoglycan/FGF2/FGF receptor complex formation and on FGF2-dependent angiogenesis in vitro and in vivo. Also, endogenous PTX3 exerts an inhibitory effect on vascularization induced by FGF2 in a murine subcutaneous Matrigel plug assay, the inhibition being abolished in Ptx3-null mice or by TSG-6 treatment in wild-type animals. Conclusion-TSG-6 reverts the inhibitory effects exerted by PTX3 on FGF2-mediated angiogenesis through competition of FGF2/PTX3 interaction. This may provide a novel mechanism to control angiogenesis in those pathological settings characterized by the coexpression of TSG-6 and PTX3, in which the relative levels of these proteins may fine-tune the angiogenic activity of FGF2. (Arterioscler Thromb Vasc Biol. 2012;32:696-703.)
A ngiogenesis, the process of new blood vessel formation from preexisting blood vessels, plays a key role in various physiological and pathological conditions, including wound healing, inflammation, and cancer. 1 The local, uncontrolled release of angiogenic growth factors and changes in the production of natural angiogenic inhibitors lead to disturbance of the angiogenic balance, 2 which is responsible for the uncontrolled neovascularization that takes place during tumor growth and angiogenesis-dependent diseases. 3 Fibroblast growth factor 2 (FGF2) is a major heparinbinding angiogenic inducer. 4 Growing evidence suggests that there is a tight cross-talk between inflammatory and angiogenic responses during FGF2-mediated neovascular-ization (reviewed in 4 ). Indeed, elevated levels of FGF2 have been implicated in the pathogenesis of several diseases characterized by a deregulated angiogenic/inflammatory response, including cancer. 4 FGF2 exerts its angiogenic activity by interacting with tyrosine-kinase FGF receptors (FGFRs) 5 and heparan sulfate proteoglycans (HSPGs) on the surface of endothelial cells (ECs) and within the extracellular matrix (ECM), 6, 7 leading to the formation of productive HSPG/FGF2/FGFR ternary complexes that provide proangiogenic signals. 8 FGF2dependent angiogenesis is further modulated by a complex network of interactions involving serum and ECM proteins and their degradation products. 9 The soluble pattern recognition receptor pentraxin 3 (PTX3), also called tumor necrosis factor-stimulated gene (TSG)-14, 10 is the prototypic member of the long pentraxin family. 11 The mature PTX3 protein is composed of 8 identical subunits held together by a disulfide bond network, where each protomer is comprised of a C-terminal pentraxin domain (as found in the short pentraxins) and a unique N-terminal region. 12, 13 PTX3 is an ECM-associated protein produced at sites of inflammation by monocytes, ECs and smooth muscle cells in response to inflammatory cytokines and bacterial components, 10, 11, 14, 15 where all of these cell types are also major sources of FGF2 in vivo. PTX3 is believed to be an inflammatory mediator with unique and nonredundant functional roles at the crossroads of innate immunity (eg, mediating complement activation and providing protection against opportunistic pathogens), fertility, and angiogenesis. 11, 16 This broad spectrum of biological activity is likely due to the structural complexity of the octameric PTX3 protein, shown recently to correspond to an elongated and asymmetric molecule composed of 2 differently sized globular lobes connected by a short stalk, 13 in which the N-and C-terminal regions of PTX3 mediate the binding to multiple ligands. 13, 17, 18 In this regard, PTX3 binds FGF2 with high affinity and specificity 19 via its N-terminal region. 13, 20 Recent work indicates that each PTX3 octamer can bind to 2 FGF2 molecules where these binding sites are composed of tetrameric assemblies of the N-terminal domain. 13 Importantly, PTX3 inhibits FGF2-dependent EC proliferation in vitro and angiogenesis in vivo. 19, 21, 22 Also, PTX3 inhibits FGF2dependent smooth muscle cell activation and intimal thickening after arterial injury. 23 Thus, PTX3 may contribute to the modulation of FGF2 activity in different pathological settings characterized by the coexpression of the 2 proteins, such as inflammation, atherosclerosis, and neoplasia (see 19, 23 for further discussion). TSG-6, the secreted product of tumor necrosis factorstimulated gene-6 (also known as TNFAIP6), is an Ϸ35-kDa protein, composed mainly of a Link module 24 and a CUB_C domain, 25 that is expressed by a wide variety of cell types, including leukocytes, smooth muscle cells, and ECs in response to inflammatory stimuli. 26 -30 For example, TSG-6 is expressed by vascular smooth muscle cells following blood vessel injury and mechanical strain 31, 32 and has been detected at sites of neovascularization in the synovium of patients with rheumatoid arthritis. 33 TSG-6 has been implicated in ECM assembly and remodeling, where it binds to a wide range of ECM components, 29, 30 including the glycosaminoglycan hyaluronan (HA), 24, 34 the heavy chains of inter-␣-inhibitor, 35, 36 and PTX3. 37 Interestingly, TSG-6, HA, inter-␣-inhibitor, and PTX3 all cooperate in the formation of an ECM around the preovulatory oocyte, 35, 37, 38 where the production of this matrix is required for successful ovulation and fertilization in vivo, and the interaction of TSG-6 with PTX3 may contribute directly to matrix stabilization via the formation of PTX3/TSG-6/HA complexes. 37 Notably, the coordinated expression of TSG-6 and PTX3 by leukocytes (in inflammatory infiltrates) and ECs has recently been described in inflamed tissues. 26 However, the effect of TSG-6 on the interaction of PTX3 with FGF2 and its antiangiogenic activity has not yet been investigated.
In this study, we demonstrate that TSG-6 reverts the inhibitory effects exerted by PTX3 on FGF2-mediated angiogenesis through competition of the FGF2/PTX3 interaction, pointing to a novel mechanism of modulation of the angiogenic process where the relative levels of TSG-6 and PTX3 dictate the biological activity of FGF2.
Methods
The detailed descriptions of the methods that were used in this study are provided in the online-only Data Supplement.
Solid Phase Binding Assays
Ninety-six-well microtiter plates were coated with PTX3, N-terminal (N term ) PTX3 or C-terminal (C term ) PTX3, TSG-6, Link_TSG6, or CUB_C_TSG6 and incubated with the proteins being tested for 1 hour at 37°C. Bound proteins were detected using the corresponding primary antibody. In competition experiments, bound biotinylated PTX3 (bPTX3) was revealed by incubation with alkaline phosphataseconjugated streptavidin, and absorbance was read at 405 nm.
Surface Plasmon Resonance
A BIAcore X system (BIAcore Inc, Piscataway, NJ) was used to analyze the binding of FGF2, wild-type and TSG-6 mutants, Link_TSG6, and CUB_C_TSG6 to PTX3 immobilized on CM4 sensor chips. 20 
Cross-Linking Assay

FGF2-Mediated Cell-Cell Adhesion Assay
FGFR1-overexpressing, HSPG-deficient Chinese hamster ovary cells (A745 CHO flg-1A; 50 000 cells/cm 2 ) were incubated on glutaraldehyde-fixed wild-type CHO-K1 cell monolayers with or without 1.66 nmol/L of FGF2 in the absence or presence of PTX3 or N term PTX3 (220 nmol/L) and increasing doses of TSG-6. After 2 hours at 37°C, A745 CHO flg-1A cells bound to the CHO-K1 cell monolayers were counted. 39
EC Proliferation Assay
Subconfluent cultures of ECs were incubated in medium containing 0.4% (vol/vol) fetal calf serum plus FGF2 (0.55 nmol/L) in the absence or presence of PTX3 (220 nmol/L) and increasing doses of wild-type or TSG-6 mutants or Link_TSG6. Following 24 hours of incubation, cells were trypsinized and counted. 20
Chicken Embryo Chorioallantoic Membrane Assay
Alginate beads containing vehicle or FGF2 (8 pmol) with or without PTX3 (33 pmol) and TSG-6 (83 pmol) were placed on top of the chorioallantoic membrane (CAM) at day 11 of incubation. After 72 hours, blood vessels converging toward the implant were counted under a stereomicroscope by 2 observers in a doubleblind fashion. 40
Matrigel Plug Angiogenesis Assay
Six-week-old female C57BL/6 wild-type and Ptx3 Ϫ/Ϫ 41 mice were injected subcutaneously with 400 L of Matrigel containing PBS or 4.0 pmol of FGF2, 33 pmol of TSG-6, or both. After 7 days, pellets were processed for total RNA extraction, and the levels of expression of PTX3, FGF2, TSG-6, and vascular endothelial growth factor-A were assayed by semiquantitative reverse transcription-polymerase chain reaction in representative samples. The vascular response was quantified by evaluation of the levels of expression of the endothelial marker CD31 by quantitative reverse transcription-polymerase chain reaction.
Immunohistochemistry
Sections of human atherosclerotic carotid artery specimens, human gastric carcinoma, and human pleomorphic parotid adenoma biopsies were immunostained with anti-human PTX3, anti-human TSG-6, and anti-human FGF2 polyclonal antibodies.
Throughout this article, PTX3 concentrations are expressed as concentrations of PTX3 protomer.
Results
TSG-6 Binds the N-Terminal Domain of PTX3 via the Link Module
Previous observations suggest that TSG-6 interacts with PTX3 through its Link module at a distinct site from the HA-binding surface. 37 As shown in Figure 1A , PTX3 bound to microtiter plates coated with full-length human TSG-6 or with its Link module domain (Link_TSG6), whereas little or no interaction was observed when a recombinant preparation of the CUB_C domain (CUB_C_TSG6) was applied. Accordingly, real-time surface plasmon resonance analysis showed that both full-length TSG-6 and Link_TSG6, but not CUB_C_TSG6, bound PTX3 immobilized to the sensor chip ( Figure 1B ). Kinetic fitting of sensorgrams gave equilibrium dissociation constants (k d ) of 314 and 648 nmol/L for the binding of full-length TSG-6 and Link_TSG6 to PTX3, respectively ( Figure I in the online-only Data Supplement). Similar results were obtained when Scatchard plot regression was performed on binding data acquired under steady-state conditions (data not shown).
Consistent with the observation that PTX3 and HA recognize distinct surfaces on TSG-6, 37 the TSG-6 Tyr94Phe mutant, which has greatly reduced (Ϸ100-fold) HA-binding activity ( 42 and A.J. Day, unpublished data, 2010), has a similar affinity as wild-type TSG-6 for PTX3 ( Figure I in the online-only Data Supplement). Conversely, the TSG-6 Tyr47Phe mutant, which also has greatly impaired HA-binding activity (A.J. Day, unpublished data, 2010), binds PTX3 with somewhat lower affinity than wild-type TSG-6 (Ϸ6-fold), suggesting that this amino acid may participate to some extent in PTX3 binding. Mutation of Glu183, located within the CUB module, to Ser (TSG-6 Glu183Ser ) (A.J. Day, unpublished data, 2010), had no affect on PTX3 binding, consistent with the finding that the CUB_C domain did not play a part in the interaction ( Figure I in the online-only Data Supplement). Taken together, these results demonstrate that the Link module, rather than the CUB_C domain, mediates the binding of TSG-6 to PTX3 and that this interaction occurs with an affinity similar to that reported for FGF2/PTX3 interaction (k d ϭ300 nmol/L 20 ).
To identify which region of the PTX3 molecule is involved in the interaction with TSG-6, microtiter plates coated with recombinant forms of the N-terminal and C-terminal domains of PTX3 (N term PTX3 and C term PTX3, respectively) were incubated with TSG-6. As shown in Figure 2A , TSG-6 bound to immobilized N term PTX3 in a concentration-dependent manner, similar to that seen with the full-length PTX3 protein, whereas no interaction of TSG-6 with C term PTX3 was observed. Accordingly, Link_TSG6 bound immobilized full-length PTX3 and N term PTX3 but not C term PTX3, whereas CUB_C_TSG6 did not interact with any of the PTX3 do-mains ( Figure 2B ). Therefore, it can be concluded that PTX3 interacts with the Link module of TSG-6 via its N-terminal domain, which is also the site where FGF2 binds. 13, 20, 43 TSG-6 Inhibits the PTX3/FGF2 Interaction As described above, TSG-6 and FGF2 both bind PTX3 with similar affinities where these interactions are mediated via the N-terminal region of PTX3. This suggests that TSG-6 might Bound protein was detected using the anti-human PTX3 polyclonal antibody ␣PTX3pb. Data are expressed as meanϮSD (nϭ12). B, TSG-6, Link_TSG6 and CUB_C_TSG6 were injected onto a PTX3-coated sensor chip, and protein binding was monitored by surface plasmon resonance (BIAcore). Sensorgrams are representative of the binding response at an analyte concentration of 300 nmol/L. be able to modulate the interaction of PTX3 with FGF2. Indeed, TSG-6 competed for the binding of biotinylated PTX3 (bPTX3) to microtiter plates coated with FGF2 with a potency (IC 50 Ϸ100 nmol/L) similar to that of nonbiotinylated PTX3, here used as a positive control ( Figure 3A) . Also, TSG-6 inhibits the binding of N term PTX3 fragment to immobilized FGF2 (Figure 3B ), whereas the short pentraxin serum amyloid P component, which is homologous to the C-terminal domain of PTX3 but does not bind FGF2 and TSG-6, 17 had no affect on bPTX3/FGF2 interaction. Furthermore, TSG-6 inhibited the chemical cross-linking of the FGF2/PTX3 complex in solution ( Figure II in the online-only Data Supplement). Thus, TSG-6 acts as an inhibitor of the FGF2 interaction with PTX3. 
TSG-6 Restores HSPG/FGF2/FGFR Ternary Complex Formation Inhibited by PTX3
FGF2 exerts its biological activity by leading to the formation of a proangiogenic HSPG/FGF2/FGFR ternary complex in ECs. 8 In keeping with its FGF2-antagonist activity, PTX3 inhibits the formation of this ternary complex in a cell-cell adhesion assay 39, 44 in which FGF2 mediates the interaction of HSPG-deficient CHO cells stably transfected with FGFR1 to a monolayer of CHO cells expressing HSPGs but not FGFRs ( Figure 4A) . To investigate the effect of TSG-6 on the inhibitory activity exerted by PTX3 on HSPG/FGF2/FGFR ternary complex formation, cells were incubated with varying concentrations of TSG-6 in the presence of constant amounts of FGF2 and PTX3. As shown in Figure 4A , TSG-6 restored FGF2-mediated cell-cell adhesion (ie, the formation of the intercellular HSPG/FGF2/FGFR complex) in a dosedependent fashion. It must be pointed out that TSG-6 alone (ie, in the absence of FGF2 and PTX3) did not induce cell-cell interaction, nor did it affect the FGF2-mediated formation of the HSPG/FGF2/FGFR complex when PTX3 was omitted. Similarly, TSG-6 also reversed the inhibitory effect of the N term PTX3 fragment on HSPG/FGF2/FGFR complex formation ( Figure III in the online-only Data Supplement). These data indicate that TSG-6 can rescue the PTX3-mediated inhibition of FGF2 engagement with its receptors, presumably via its competition for the PTX-FGF2 interaction.
TSG-6 Suppresses the Inhibitory Effect of PTX3 on FGF2-Dependent Angiogenesis
PTX3 inhibits the mitogenic activity exerted by FGF2 on ECs, without affecting the activity of unrelated mitogens. 19 On this basis, TSG-6 was assessed for its capacity to reverse the inhibition caused by PTX3 on FGF2-dependent EC proliferation. To this end, fetal bovine aortic GM7373 ECs were incubated with FGF2 (0.56 nmol/L), PTX3 (220 nmol/ L), and a range of TSG-6 concentrations. Consistent with its ability to restore HSPG/FGF2/FGFR ternary complex formation inhibited by PTX3, increasing doses of TSG-6 progressively restored FGF2-induced EC proliferation in the presence of PTX3 ( Figure 4B) . A similar effect was also seen with the TSG-6 mutants TSG-6 Tyr47Phe , TSG-6 Tyr94Phe , and TSG-6 Glu183Ser ( Figure IV in the online-only Data Supplement), which all retain binding to PTX3 (see Figure I in the online-only Data Supplement). It should be noted that TSG-6 alone did not affect EC proliferation when tested in the absence or in the presence of FGF2 ( Figure 4B) .
To further confirm the capacity of TSG-6 to restore EC proliferation by preventing FGF2/PTX3 interaction, we took advantage of an experimental model in which human PTX3 or the N term PTX3 fragment are endogenously expressed by retrovirus-infected murine aortic ECs (PTX3_MAECs and N term PTX3_MAECs, respectively) and inhibit EC proliferation in response to exogenous FGF2. 20 As shown in Figure 4C and 4D, increasing doses of TSG-6 progressively restored the capacity of PTX3_MAEC and N term PTX3_MAEC transfectants to proliferate in response to FGF2. Again, similar activities were seen with the TSG-6 mutant proteins ( Figure  IV in the online-only Data Supplement). These and the data Figure 4 . TSG-6 suppresses the inhibitory effect exerted by pentraxin 3 (PTX3) on fibroblast growth factor 2 (FGF2) activity. A, FGF receptor 1 (FGFR1)-overexpressing, heparan sulfate proteoglycan (HSPG)-deficient Chinese hamster ovary (CHO) cells were incubated on a monolayer of CHO-K1 cells with FGF2 (1.66 nmol/L) and the indicated amounts of TSG-6 in the absence (E) or presence (F) of PTX3 (220 nmol/L). After 2 hours, bound cells were counted under an inverted microscope. Data are expressed as percentage of the cell-cell adhesion induced by FGF2 alone. Binding of TSG-6-treated cells in the absence of FGF2 and PTX3 is shown as control (Ⅺ). B, GM7373 cells were incubated with 0.4% fetal calf serum (FCS) containing 0.56 nmol/L FGF2 and the reported concentrations of TSG-6 in the absence (E) or presence (F) of PTX3 (220 nmol/L). After 24 hours, cells were trypsinized and counted. Data are expressed as percentage of GM7373 cells stimulated with FGF2 only. The proliferation of GM7373 cells treated with TSG-6 only (ie, in the absence of FGF2 and PTX3) is shown as a control (Ⅺ). C and D, Retrovirus-infected PTX3 cells overexpressing PTX3 (PTX3_MAECs) (where MAEC indicates murine aortic EC) (C) or N-terminal (N term ) PTX3 (N term PTX3_MAECs (D) were incubated with 0.4% FCS plus 0.56 nmol/L FGF2 and the indicated amounts of TSG-6 (F). Following 24 hours of incubation, cells were trypsinized and counted. Data are expressed as percentage of the proliferation measured in mock-infected cells stimulated with FGF2 only. The proliferation of cells treated with TSG-6 alone is shown as a control (E). In all graphs, intermediate markings on the x axis represent the actual concentrations of TSG-6 used in the different assays. Data are the meanϮSD of 3 experiments performed in triplicate.
above demonstrate that neither the HA-binding function of TSG-6 24 nor its ability to form covalent complexes with the heavy chains of inter-␣-inhibitor 36 (ie, properties impaired in these mutants) is necessary for TSG-6 to show activity in these angiogenesis assay systems.
The capacity of TSG-6 and PTX3 to affect FGF2-induced neovascularization in vivo was then investigated in a chicken embryo CAM angiogenesis assay 45 and in a murine subcutaneous Matrigel plug assay. 46 In the CAM assay, alginate beads adsorbed with FGF2 (8.0 pmol/embryo) exerted a potent angiogenic response when applied on the top of the CAM as compared with beads adsorbed with vehicle. Consistent with the in vitro observations, the angiogenic response elicited by FGF2 was significantly reduced by the addition of 33 pmol of PTX3 to the FGF2 implants (PϽ0.001), and this inhibition was fully abolished by coadministration of 83 pmol of TSG-6. No effect on CAM vascularization was instead exerted by TSG-6 alone ( Figure 5A) .
Next, the effect of TSG-6 on FGF2-induced angiogenesis was assessed in wild-type and Ptx3-null mice using a subcutaneous Matrigel plug assay ( Figure 5B ). It must be pointed out that the subcutaneous injection of Matrigel induces, per se, a mild proinflammatory reaction, 47 leading to the coexpression within the plug of PTX3, FGF2, TSG-6, and vascular endothelial growth factor-A transcripts ( Figure V in the online-only Data Supplement). Also, no significant difference in the levels of FGF2, TSG-6, and vascular endothelial growth factor-A expression occurred in PBS-treated Matrigel plugs injected in Ptx3-null mice compared with plugs implanted in wild-type animals ( Figure V in the online-only Data Supplement). Consistent with the FGF2-antagonist activity of PTX3, we observed a significant increase of vascularization in both PBS-treated and FGF2-treated plugs implanted in Ptx3-deficient mice compared with wild-type animals, as assessed by quantitative reverse transcriptionpolymerase chain reaction analysis of the levels of expression of the endothelial marker CD31 in the Matrigel plugs. 48 A similar increase was observed when TSG-6 was added to PBS-treated and FGF2-treated Matrigel plugs implanted in wild-type animals, no further significant increase in vascularization being exerted by TSG-6 in Ptx3-null mice ( Figure 5B ).
Discussion
Taken together, the above results indicate that TSG-6 suppresses the inhibition exerted by PTX3 on FGF2-dependent angiogenesis both in vitro and in vivo. Thus, this provides the first direct evidence of a role for TSG-6 as a modulator of neovascularization. Our observations clearly indicate that TSG-6 exerts its "proangiogenic " functions via inhibition of the PTX3/FGF2 interaction, where this may be mediated by the binding of TSG-6 to PTX3. Preliminary solid phase binding and surface plasmon resonance assays suggest that TSG-6 may also interact directly with FGF2 (A. Inforzato and A.J. Day, unpublished data, 2009 ). Thus, TSG-6 might prevent FGF2/PTX3 interaction through a combination of mechanisms that together lead to suppression of the inhibition exerted by PTX3 on the angiogenic activity of FGF2. Further work is required to fully dissect the molecular interplay between PTX3, FGF2, and TSG-6 so as to understand the mechanism of TSG-6 action.
As described above, PTX3 may contribute to the modulation of FGF2-driven angiogenesis in different pathological settings characterized by the coexpression of the 2 proteins, including Figure 5 . TSG-6/pentraxin 3 (PTX3) cross-talk modulates fibroblast growth factor 2 (FGF2)-mediated angiogenesis in vivo. A, Chicken embryo chorioallantoic membranes (CAMs) were implanted at day 11 with alginate beads containing FGF2 (8 pmol), PTX3 (33 pmol), and TSG-6 (83 pmol) or combinations of these proteins. At day 14, newly formed thin blood microvessels converging toward the implant in a spoke-wheel pattern (readily distinguishable from preexisting, larger vessels with no directionality) 45 were counted. CAM implants that contained vehicle (phosphatebuffered saline [PBS]) or TSG-6 only were used as controls. Data are the meanϮSD (nϭ7-11). *PϽ0.01, Student t test. B, Wild-type (open bars) and Ptx3-null mice (black bars) were injected subcutaneously with Matrigel plugs containing PBS or 4 pmol of FGF2, 33 pmol of TSG-6, or both. After 7 days, pellets were processed for total RNA extraction, and the vascular response was quantified by reverse transcription-polymerase chain reaction analysis of the expression of the endothelial marker CD31. Data are the meanϮSEM (nϭ8 -10). *PϽ0.05 or better; n.s. indicates not statistically significant; Student t test.
inflammation, wound healing, atherosclerosis, and neoplasia (see 44, 49 for further discussion). The coordinated expression of TSG-6 and PTX3 has been described in inflamed tissues 26, 50 and in the cumulus oophorus. 37, 50 Accordingly, FGF2, TSG-6, and PTX3 are coexpressed following subcutaneous injection of a Matrigel plug in mice (see Figure V in the online-only Data Supplement), a mildly proinflammatory experimental condition. 47 Moreover, immunohistochemical analysis performed on a limited series of human specimens shows that FGF2, TSG-6, and PTX3 are coexpressed in human atherosclerotic carotid artery and in biopsies of human benign tumors (pleomorphic parotid adenoma) and cancer (gastric carcinoma) 51, 52 (Figure VI in the online-only Data Supplement). Additional studies on larger cohorts of patients will be required to assess the relationship between the expression of these modulators of the angiogenic process and tissue vascularization in different inflammatory/cancerous conditions.
Our study indicates that the relative levels of TSG-6 and PTX3 likely dictate the biological activity of FGF2; a low TSG-6:PTX3 ratio exerts an inhibitory effect on FGF2-mediated angiogenesis, whereas an high TSG-6:PTX3 ratio represents a permissive condition for the angiogenic activity of the growth factor. Thus, the interaction of TSG-6 and PTX3 might act as a biological rheostat for FGF2-dependent neovascularization, contributing to the complex extracellular protein interactome 9 that mediates the angiogenic process. These conclusions are supported by the observation that endogenous PTX3 exerts a significant inhibitory effect on vascularization induced by endogenous FGF2 or by the exogenously added growth factor in a murine Matrigel plug assay, this effect being abolished in Ptx3-null mice or by TSG-6 treatment in wild-type animals. As anticipated, no effect is exerted by TSG-6 in the absence of endogenous PTX3, ie, in Ptx3-null mice.
Our studies indicate that TSG-6 can act as a novel indirect proangiogenic cofactor by releasing FGF2 from the PTX3 constraints, no direct angiogenic activity being exerted by this protein when administered alone in the different assays. On the other hand, recent data have shown that intraocular TSG-6 treatment in a rat model of corneal wound healing can inhibit neovascularization, 53 possibly as a consequence of its antiinflammatory activity (eg, inhibition of neutrophil infiltration). 30 Notably, the antiangiogenic and anti-inflammatory effects were observed only when TSG-6 was administered within 4 hours after injury, no effect being observed when the inflammatory cell infiltrate was already established. 30 Previous observations had shown that some anti-inflammatory cytokines, including erythropoietin 54 and interleukin-10 55 may promote angiogenesis, whereas tumor necrosis factor-␣ may exert pro-or antiangiogenic effects depending on the dose of the cytokine. 56 Taken together, these data suggest that TSG-6 may have both proangiogenic and antiangiogenic properties, such that the balance between promotion and inhibition of neovascularization may depend on context (eg, the microenvironment). Further research is needed to investigate the precise role of TSG-6 as a modulator of angiogenesis and how this is regulated, for example, by components of the ECM.
